Alithea Genomics
The company develops and provides high-throughput transcriptomics kits and services, including its proprietary MERCURIUS technology for bulk and single-cell RNA sequencing. Its products enable extraction-free library preparation and massive sample multiplexing directly from cells, blood, plants, and organoids. These solutions are designed for pharmaceutical, biotech, and academic researchers performing large-scale drug discovery, toxicology testing, and gene expression studies.
Visit websiteLausanne, Switzerland
Biotechnology
Genomics
Life Sciences
Healthtech
Agrochemicals
Funding summary
- Total raised
- €4.9M
- Funding rounds
- 4
Investors in Alithea Genomics
Investors on record for Alithea Genomics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Alithea Genomics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors